Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Unknown 4Terminated 3Recruiting 3Not yet recruiting 2Completed 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 2Breast 1

Conditions

Carcinoma, Non-Small-Cell Lung 26Lung Neoplasms 5Small Cell Lung Carcinoma 2Pancreatic Neoplasms 2Neoplasm Metastasis 2NSCLC 2Brain Neoplasms 2Solid Tumor Cancer 1Non-squamous Non-small Cell Lung Cancer 1Non-small Cell Lung Cancer Metastatic 1Non Squamous Non-small Cell Lung Cancer 1Neoplasms 1Mesothelioma, Malignant 1Meningeal Carcinomatosis 1Melanoma 1Lymphatic Metastasis 1Lung Non-Squamous Non-Small Cell Carcinoma 1Lung Diseases, Interstitial 1Gastrointestinal Neoplasms 1Esophageal Neoplasms 1Disease Progression 1Diabetes Mellitus, Insulin-Dependent, 12 1Colorectal Neoplasms 1Colonic Neoplasms 1Carcinoma 1Advanced Solid Tumor 1Adenocarcinoma of Lung 1

Interventions

Drug Therapy 3Carboplatin 3Surgical Procedures, Operative 2Pemetrexed 2Paclitaxel 2Cisplatin 2toripalimab 1tislelizumab 1surufatinib 1osimertinib 1lorlatinib 1anlotinib 1Radiotherapy 1Radiosurgery 1Platinum Compounds 1Neoadjuvant Therapy 1Diphenhydramine 1Cryotherapy 1Chemotherapy, Adjuvant 1Chemoradiotherapy 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Not yet recruiting × NSCLC × Pemetrexed × Clear all
NCT06944470 2025-04-25

JS207 Combined With Chemotherapy in Subjects With Stage II-III NSCLC

Shanghai Junshi Bioscience Co., Ltd.

Phase 2 Not yet recruiting
76 enrolled
Thoracic

NSCLC

NCT06746870 2024-12-24

A Phase II Clinical Study to Evaluate the Safety, Pharmacokinetic Profile, and Preliminary Efficacy of IMM2510 in Combination with Chemotherapy As First-line Treatment in Subjects with Non-small Cell Lung Cancer or Triple-negative Breast Cancer

ImmuneOnco Biopharmaceuticals (Shanghai) Inc.

Phase 2 Not yet recruiting
148 enrolled
BreastThoracic

NSCLC

Data powered by HemOnc (CC BY 4.0) Colophon âš¡